HDAC9 and neoplasm: HDAC inhibitors can increase the immunogenicity of cancer in numerous ways, including the upregulation of the expression of tumor antigens, tumor antigen presentation on antigen-presenting cells and co-stimulation molecules in cancer cells (Figure 4).